Skip to main content

Advertisement

SpringerLink
Log in

Recent and Emerging Therapies for Cutaneous Squamous Cell Carcinomas of the Head and Neck

  • Head and Neck Cancer (CP Rodriguez, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Cutaneous squamous cell carcinoma (cSCC) of the head and neck is typically managed with Mohs Micrographic Surgery (MMS) for cosmetic reasons. MMS also improves oncologic outcomes for high-risk tumors. Patients with certain high-risk subsets of the disease also benefit from adjuvant radiation therapy. The PD-1 inhibitor, cemiplimab, was recently approved for treatment of locally advanced and metastatic cSCC unamenable to curative surgery or radiation therapy after the drug demonstrated encouraging, durable response rates. Cemiplimab and other systemic immunotherapies are now being evaluated in clinical trials in the neoadjuvant and adjuvant settings as well. Localized immunotherapies are also being studied, including oncolytic viruses such as talimogene laherparepvec, a modified herpes simplex virus previously approved for the treatment of advanced cutaneous melanoma. Most importantly, multidisciplinary care is crucial in optimizing outcomes for patients with high-risk cSCC of the head and neck.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Que SKT, Zwald FO, Schmults CD. Cutaneous squamous cell carcinoma: incidence, risk factors, diagnosis, and staging. J Am Acad Dermatol. 2018;78(2):237–47. https://doi.org/10.1016/j.jaad.2017.08.059.

    Article  PubMed  Google Scholar 

  2. Armstrong BK, Kricker A. The epidemiology of UV induced skin cancer. J Photochem Photobiol B. 2001;63(1–3):8–18.

    Article  CAS  Google Scholar 

  3. Alam M, Ratner D. Cutaneous squamous-cell carcinoma. N Engl J Med. 2001;344(13):975–83. https://doi.org/10.1056/NEJM200103293441306.

    Article  CAS  PubMed  Google Scholar 

  4. Amin MB, American Joint Committee on Cancer., American Cancer Society. AJCC cancer staging manual. Eight edition / editor-in-chief, Mahul B. Amin, MD, FCAP ; editors, Stephen B. Edge, MD, FACS and 16 others ; Donna M. Gress, RHIT, CTR - Technical editor ; Laura R. Meyer, CAPM - Managing editor. ed. Chicago: American Joint Committee on Cancer, Springer; 2017.

  5. Karia PS, Jambusaria-Pahlajani A, Harrington DP, Murphy GF, Qureshi AA, Schmults CD. Evaluation of American Joint Committee on Cancer, International Union Against Cancer, and Brigham and Women’s Hospital tumor staging for cutaneous squamous cell carcinoma. J Clin Oncol. 2014;32(4):327–34. https://doi.org/10.1200/JCO.2012.48.5326.

    Article  PubMed  Google Scholar 

  6. Ruiz ES, Karia PS, Besaw R, Schmults CD. Performance of the American Joint Committee on Cancer staging manual, 8th edition vs the Brigham and Women’s Hospital tumor classification system for cutaneous squamous cell carcinoma. JAMA Dermatol. 2019;155(7):819–25. https://doi.org/10.1001/jamadermatol.2019.0032.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Breuninger H, Brantsch K, Eigentler T, Hafner HM. Comparison and evaluation of the current staging of cutaneous carcinomas. J Dtsch Dermatol Ges. 2012;10(8):579–86. https://doi.org/10.1111/j.1610-0387.2012.07896.x.

    Article  PubMed  Google Scholar 

  8. Lansbury L, Bath-Hextall F, Perkins W, Stanton W, Leonardi-Bee J. Interventions for non-metastatic squamous cell carcinoma of the skin: systematic review and pooled analysis of observational studies. BMJ. 2013;347:f6153. https://doi.org/10.1136/bmj.f6153.

    Article  PubMed  PubMed Central  Google Scholar 

  9. • Marrazzo G, Zitelli JA, Brodland D. Clinical outcomes in high-risk squamous cell carcinoma patients treated with Mohs micrographic surgery alone. J Am Acad Dermatol. 2019;80(3):633–8. https://doi.org/10.1016/j.jaad.2018.09.015. Large retrospective study demonstrating low rates of poor outcomes in patients with high-risk cutaneous squamous cell carcinoma treated with Mohs micrographic surgery alone.

    Article  PubMed  Google Scholar 

  10. Ad Hoc Task F, Connolly SM, Baker DR, Coldiron BM, Fazio MJ, Storrs PA, et al. AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery: a report of the American Academy of Dermatology, American College of Mohs Surgery, American Society for Dermatologic Surgery Association, and the American Society for Mohs Surgery. J Am Acad Dermatol. 2012;67(4):531–50. https://doi.org/10.1016/j.jaad.2012.06.009.

    Article  Google Scholar 

  11. Manyam BV, Joshi N, Koyhman S. A review of the role of external-beam radiation therapy in nonmelanomatous skin cancer. Appl Rad Oncol. 2017;6:6–10.

    Google Scholar 

  12. Koyfman SA, Cooper JS, Beitler JJ, Busse PM, Jones CU, McDonald MW, et al. ACR appropriateness criteria((R)) aggressive nonmelanomatous skin cancer of the head and neck. Head Neck. 2016;38(2):175–82. https://doi.org/10.1002/hed.24171.

    Article  PubMed  Google Scholar 

  13. National Comprehensive Cancer Network. Squamous cell skin cancer (Version 2.2019). https://www.nccn.org/professionals/physician_gls/pdf/squamous.pdf. Accessed July 30, 2019.

  14. Veness MJ, Morgan GJ, Palme CE, Gebski V. Surgery and adjuvant radiotherapy in patients with cutaneous head and neck squamous cell carcinoma metastatic to lymph nodes: combined treatment should be considered best practice. Laryngoscope. 2005;115(5):870–5. https://doi.org/10.1097/01.MLG.0000158349.64337.ED.

    Article  PubMed  Google Scholar 

  15. • Harris BN, Pipkorn P, Nguyen KNB, Jackson RS, Rao S, Moore MG, et al. Association of adjuvant radiation therapy with survival in patients with advanced cutaneous squamous cell carcinoma of the head and neck. JAMA Otolaryngol Head Neck Surg. 2019;145(2):153–8. https://doi.org/10.1001/jamaoto.2018.3650. Large retrospective study showing association of adjuvant radiation therapy with improved survival for cutaneous squamous cell carcinoma patients with perineural invasion and patients with regional disease.

    Article  PubMed  Google Scholar 

  16. Manyam BV, Garsa AA, Chin RI, Reddy CA, Gastman B, Thorstad W, et al. A multi-institutional comparison of outcomes of immunosuppressed and immunocompetent patients treated with surgery and radiation therapy for cutaneous squamous cell carcinoma of the head and neck. Cancer. 2017;123(11):2054–60. https://doi.org/10.1002/cncr.30601.

    Article  CAS  PubMed  Google Scholar 

  17. Jambusaria-Pahlajani A, Miller CJ, Quon H, Smith N, Klein RQ, Schmults CD. Surgical monotherapy versus surgery plus adjuvant radiotherapy in high-risk cutaneous squamous cell carcinoma: a systematic review of outcomes. Dermatol Surg. 2009;35(4):574–85.

    Article  CAS  Google Scholar 

  18. Tanvetyanon T, Padhya T, McCaffrey J, Kish JA, Deconti RC, Trotti A, et al. Postoperative concurrent chemotherapy and radiotherapy for high-risk cutaneous squamous cell carcinoma of the head and neck. Head Neck. 2015;37(6):840–5. https://doi.org/10.1002/hed.23684.

    Article  PubMed  Google Scholar 

  19. Porceddu SV, Bressel M, Poulsen MG, Stoneley A, Veness MJ, Kenny LM, et al. Postoperative concurrent chemoradiotherapy versus postoperative radiotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck: the randomized phase III TROG 05.01 trial. J Clin Oncol. 2018;36(13):1275–83. https://doi.org/10.1200/JCO.2017.77.0941.

    Article  CAS  PubMed  Google Scholar 

  20. O'Bryan K, Sherman W, Niedt GW, Taback B, Manolidis S, Wang A, et al. An evolving paradigm for the workup and management of high-risk cutaneous squamous cell carcinoma. J Am Acad Dermatol. 2013;69(4):595–602 e1. https://doi.org/10.1016/j.jaad.2013.05.011.

    Article  PubMed  Google Scholar 

  21. Trodello C, Higgins S, Ahadiat O, Ragab O, In G, Hawkins M, et al. Cetuximab as a component of multimodality treatment of high-risk cutaneous squamous cell carcinoma: a retrospective analysis from a single tertiary academic medical center. Dermatol Surg. 2019;45(2):254–67. https://doi.org/10.1097/DSS.0000000000001755.

    Article  CAS  PubMed  Google Scholar 

  22. Sadek H, Azli N, Wendling JL, Cvitkovic E, Rahal M, Mamelle G, et al. Treatment of advanced squamous cell carcinoma of the skin with cisplatin, 5-fluorouracil, and bleomycin. Cancer. 1990;66(8):1692–6. https://doi.org/10.1002/1097-0142(19901015)66:8<1692::aid-cncr2820660807>3.0.co;2-y.

    Article  CAS  PubMed  Google Scholar 

  23. Jarkowski A 3rd, Hare R, Loud P, Skitzki JJ, Kane JM 3rd, May KS, et al. Systemic therapy in advanced cutaneous squamous cell carcinoma (CSCC): the Roswell Park experience and a review of the literature. Am J Clin Oncol. 2016;39(6):545–8. https://doi.org/10.1097/COC.0000000000000088.

    Article  CAS  PubMed  Google Scholar 

  24. Maubec E, Petrow P, Scheer-Senyarich I, Duvillard P, Lacroix L, Gelly J, et al. Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin. J Clin Oncol. 2011;29(25):3419–26. https://doi.org/10.1200/JCO.2010.34.1735.

    Article  CAS  PubMed  Google Scholar 

  25. Reigneau M, Robert C, Routier E, Mamelle G, Moya-Plana A, Tomasic G, et al. Efficacy of neoadjuvant cetuximab alone or with platinum salt for the treatment of unresectable advanced nonmetastatic cutaneous squamous cell carcinomas. Br J Dermatol. 2015;173(2):527–34. https://doi.org/10.1111/bjd.13741.

    Article  CAS  PubMed  Google Scholar 

  26. William WN Jr, Feng L, Ferrarotto R, Ginsberg L, Kies M, Lippman S, et al. Gefitinib for patients with incurable cutaneous squamous cell carcinoma: a single-arm phase II clinical trial. J Am Acad Dermatol. 2017;77(6):1110–3 e2. https://doi.org/10.1016/j.jaad.2017.07.048.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  27. Gold KA, Kies MS, William WN Jr, Johnson FM, Lee JJ, Glisson BS. Erlotinib in the treatment of recurrent or metastatic cutaneous squamous cell carcinoma: a single-arm phase 2 clinical trial. Cancer. 2018;124(10):2169–73. https://doi.org/10.1002/cncr.31346.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Foote MC, McGrath M, Guminski A, Hughes BG, Meakin J, Thomson D, et al. Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma. Ann Oncol. 2014;25(10):2047–52. https://doi.org/10.1093/annonc/mdu368.

    Article  CAS  PubMed  Google Scholar 

  29. Cavalieri S, Perrone F, Miceli R, Ascierto PA, Locati LD, Bergamini C, et al. Efficacy and safety of single-agent pan-human epidermal growth factor receptor (HER) inhibitor dacomitinib in locally advanced unresectable or metastatic skin squamous cell cancer. Eur J Cancer. 2018;97:7–15. https://doi.org/10.1016/j.ejca.2018.04.004.

    Article  CAS  PubMed  Google Scholar 

  30. Que SKT, Zwald FO, Schmults CD. Cutaneous squamous cell carcinoma: management of advanced and high-stage tumors. J Am Acad Dermatol. 2018;78(2):249–61. https://doi.org/10.1016/j.jaad.2017.08.058.

    Article  PubMed  Google Scholar 

  31. Choi FD, Kraus CN, Elsensohn AN, Carley SK, Lehmer LM, Nguyen RT, et al. PD-1 and PD-L1 inhibitors in the treatment of non-melanoma skin cancer: a systematic review. J Am Acad Dermatol. 2019. https://doi.org/10.1016/j.jaad.2019.05.077.

  32. Liu Y, Fitzgerald B, Perry E, Pathak A, Chao HH. Prolonged response to pembrolizumab in spindle cell squamous cell carcinoma metastatic to the central nervous system. J Investig Med High Impact Case Rep. 2019;7:2324709619850216. https://doi.org/10.1177/2324709619850216.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Oliveira LJC, Gongora ABL, Barbosa FG, Dos Anjos CH, Munhoz RR. Atypical response with bone pseudoprogression in a patient receiving nivolumab for advanced cutaneous squamous cell carcinoma. J Immunother Cancer. 2018;6(1):130. https://doi.org/10.1186/s40425-018-0444-5.

    Article  PubMed  PubMed Central  Google Scholar 

  34. van Baar MLM, Guminski AD, Ferguson PM, Martin LK. Pembrolizumab for cutaneous squamous cell carcinoma: report of a case of inoperable squamous cell carcinoma with complete response to pembrolizumab complicated by granulomatous inflammation. JAAD Case Rep. 2019;5(6):491–4. https://doi.org/10.1016/j.jdcr.2019.04.006.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Pandey A, Liaukovich M, Joshi K, Avezbakiyev BI, O’Donnell JE. Uncommon presentation of metastatic squamous cell carcinoma of the skin and treatment challenges. Am J Case Rep. 2019;20:294–9. https://doi.org/10.12659/AJCR.913488.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Day F, Kumar M, Fenton L, Gedye C. Durable response of metastatic squamous cell carcinoma of the skin to ipilimumab immunotherapy. J Immunother. 2017;40(1):36–8. https://doi.org/10.1097/CJI.0000000000000146.

    Article  PubMed  Google Scholar 

  37. Miller DM, Faulkner-Jones BE, Stone JR, Drews RE. Complete pathologic response of metastatic cutaneous squamous cell carcinoma and allograft rejection after treatment with combination immune checkpoint blockade. JAAD Case Rep. 2017;3(5):412–5. https://doi.org/10.1016/j.jdcr.2017.06.005.

    Article  PubMed  PubMed Central  Google Scholar 

  38. •• Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N Engl J Med. 2018;379(4):341–51. https://doi.org/10.1056/NEJMoa1805131. Phase 1/II trial demonstrating encouraging, durable response rates in patients with locally advanced and metastatic cutaneous squamous cell carcinoma treated with cemiplimab monotherapy.

    Article  CAS  PubMed  Google Scholar 

  39. Annals of Oncology (2019) 30 (suppl_5): v533-v563. https://doi.org/10.1093/annonc/mdz255.

  40. Kacew AJ, Harris EJ, Lorch JH, Haddad RI, Chau NG, Rabinowits G, et al. Chromosome 3q arm gain linked to immunotherapy response in advanced cutaneous squamous cell carcinoma. Eur J Cancer. 2019;113:1–9. https://doi.org/10.1016/j.ejca.2019.03.004.

    Article  CAS  PubMed  Google Scholar 

  41. Gross N, Ferrarotto R, Nagarajan P, Bell D, El-Naggar A, Johnson JM, et al. LBA74 Phase II study of neoadjuvant cemiplimab prior to surgery in patients with stage III/IV (M0) cutaneous squamous cell carcinoma of the head and neck (CSCC-HN). Ann Oncol. 2019;30(Supplement_5). https://doi.org/10.1093/annonc/mdz394.071.

  42. Fromm G, de Silva S, Johannes K, Patel A, Hornblower JC, Schreiber TH. Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy. J Immunother Cancer. 2018;6(1):149–16. https://doi.org/10.1186/s40425-018-0454-3.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Croft M. Control of immunity by the TNFR-related molecule OX40 (CD134). Annu Rev Immunol. 2010;28:57–78. https://doi.org/10.1146/annurev-immunol-030409-101243.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Owonikoko TK, Kumar M, Yang S, Kamphorst AO, Pillai RN, Akondy R, et al. Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report. Cancer Immunol Immunother. 2017;66(1):45–50. https://doi.org/10.1007/s00262-016-1918-2.

    Article  PubMed  Google Scholar 

  45. Lipson EJ, Bagnasco SM, Moore J Jr, Jang S, Patel MJ, Zachary AA, et al. Tumor regression and allograft rejection after administration of Anti-PD-1. N Engl J Med. 2016;374(9):896–8. https://doi.org/10.1056/NEJMc1509268.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Fisher J, Zeitouni N, Fan W, Samie FH. Immune checkpoint inhibitor therapy in solid organ transplant recipients: a patient-centered systematic review. J Am Acad Dermatol. 2019. https://doi.org/10.1016/j.jaad.2019.07.005.

  47. Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, et al. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol. 2015;33(25):2780–8. https://doi.org/10.1200/JCO.2014.58.3377.

    Article  CAS  PubMed  Google Scholar 

  48. Conry RM, Westbrook B, McKee S, Norwood TG. Talimogene laherparepvec: first in class oncolytic virotherapy. Hum Vaccin Immunother. 2018;14(4):839–46. https://doi.org/10.1080/21645515.2017.1412896.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Pol JG, Acuna SA, Yadollahi B, Tang N, Stephenson KB, Atherton MJ, et al. Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials. Oncoimmunology. 2019;8(1):e1512329. https://doi.org/10.1080/2162402X.2018.1512329.

    Article  PubMed  Google Scholar 

  50. LaRocca CJ, Warner SG. Oncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials. Clin Transl Med. 2018;7(1):35. https://doi.org/10.1186/s40169-018-0214-5.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Wang J, Aldabagh B, Yu J, Arron ST. Role of human papillomavirus in cutaneous squamous cell carcinoma: a meta-analysis. J Am Acad Dermatol. 2014;70(4):621–9. https://doi.org/10.1016/j.jaad.2014.01.857.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Chahoud J, Semaan A, Chen Y, Cao M, Rieber AG, Rady P, et al. Association between beta-genus human papillomavirus and cutaneous squamous cell carcinoma in Immunocompetent individuals-a meta-analysis. JAMA Dermatol. 2016;152(12):1354–64. https://doi.org/10.1001/jamadermatol.2015.4530.

    Article  PubMed  Google Scholar 

  53. Nichols AJ, Allen AH, Shareef S, Badiavas EV, Kirsner RS, Ioannides T. Association of human papillomavirus vaccine with the development of keratinocyte carcinomas. JAMA Dermatol. 2017;153(6):571–4. https://doi.org/10.1001/jamadermatol.2016.5703.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Nichols AJ, Gonzalez A, Clark ES, Khan WN, Rosen AC, Guzman W, et al. Combined systemic and intratumoral administration of human papillomavirus vaccine to treat multiple cutaneous basaloid squamous cell carcinomas. JAMA Dermatol. 2018;154(8):927–30. https://doi.org/10.1001/jamadermatol.2018.1748.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Kandimalla ER, Nallagatla S, Anderson BR, Kang R. Abstract A136: AST-008, a novel TLR9 agonist SNA, induces abscopal antitumor effects in mouse tumor models. Cancer Immunol Res. 2019;7(2 Supplement):A136–A. https://doi.org/10.1158/2326-6074.cricimteatiaacr18-a136.

    Article  Google Scholar 

  56. Doener F, Hong HS, Meyer I, Tadjalli-Mehr K, Daehling A, Heidenreich R, et al. RNA-based adjuvant CV8102 enhances the immunogenicity of a licensed rabies vaccine in a first-in-human trial. Vaccine. 2019;37(13):1819–26. https://doi.org/10.1016/j.vaccine.2019.02.024.

    Article  CAS  PubMed  Google Scholar 

  57. Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, et al. Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 2017;376(23):2211–22. https://doi.org/10.1056/NEJMoa1613210.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Sadeghi R, Adinehpoor Z, Maleki M, Fallahi B, Giovanella L, Treglia G. Prognostic significance of sentinel lymph node mapping in Merkel cell carcinoma: systematic review and meta-analysis of prognostic studies. Biomed Res Int. 2014;2014:489536. https://doi.org/10.1155/2014/489536.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Tejera-Vaquerizo A, Garcia-Doval I, Llombart B, Canueto J, Martorell-Calatayud A, Descalzo-Gallego MA, et al. Systematic review of the prevalence of nodal metastases and the prognostic utility of sentinel lymph node biopsy in cutaneous squamous cell carcinoma. J Dermatol. 2018;45(7):781–90. https://doi.org/10.1111/1346-8138.14342.

    Article  PubMed  Google Scholar 

  60. Lhote R, Lambert J, Lejeune J, Gottlieb J, Badaoui A, Battistella M, et al. Sentinel lymph node biopsy in cutaneous squamous cell carcinoma series of 37 cases and systematic review of the literature. Acta Derm Venereol. 2018;98(7):671–6. https://doi.org/10.2340/00015555-2942.

    Article  PubMed  Google Scholar 

  61. Koyfman SA, Joshi N, Vidimos A. Adjuvant radiotherapy in high-risk cutaneous squamous cell cancer of the head and neck in immunosuppressed patients. JAAD Case Rep. 2015;1(6):S5–7. https://doi.org/10.1016/j.jdcr.2015.09.016.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Romesser PB, Cahlon O, Scher E, Zhou Y, Berry SL, Rybkin A, et al. Proton beam radiation therapy results in significantly reduced toxicity compared with intensity-modulated radiation therapy for head and neck tumors that require ipsilateral radiation. Radiother Oncol. 2016;118(2):286–92. https://doi.org/10.1016/j.radonc.2015.12.008.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Umebayashi Y, Uyeno K, Tsujii H, Otsuka F. Proton radiotherapy of skin carcinomas. Br J Dermatol. 1994;130(1):88–91. https://doi.org/10.1111/j.1365-2133.1994.tb06889.x.

    Article  CAS  PubMed  Google Scholar 

  64. Bryant CM, Dagan R, Li Z, Morris CG, Mendenhall WM. Proton therapy for nonmelanoma skin cancers with clinical perineural invasion. Int J Radiat Oncol Biol Phys. 2017;99(2):E324–E5. https://doi.org/10.1016/j.ijrobp.2017.06.1376.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Case Western Reserve University School of Medicine, Cleveland, OH, USA

    Vamsi Varra BS

  2. Cleveland Clinic Foundation, Cleveland, OH, USA

    Timothy D. Smile MD, Jessica L. Geiger MD & Shlomo A. Koyfman MD

Authors
  1. Vamsi Varra BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Timothy D. Smile MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jessica L. Geiger MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shlomo A. Koyfman MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Vamsi Varra BS.

Ethics declarations

Conflict of interest

Vamsi Varra declares that he has no conflict of interest.

Timothy D. Smile declares that he has no conflict of interest.

Jessica L. Geiger has received institutional research funding from Genentech and Regeneron, and has received advisory board honoraria from Regeneron.

Shlomo A. Koyfman has received research funding from Merck and Bristol-Myers Squibb, and has received honoraria from UpToDate and Varian Medical Systems.

Human and animal rights and informed consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical collection on Head and Neck Cancer

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Varra, V., Smile, T.D., Geiger, J.L. et al. Recent and Emerging Therapies for Cutaneous Squamous Cell Carcinomas of the Head and Neck. Curr. Treat. Options in Oncol. 21, 37 (2020). https://doi.org/10.1007/s11864-020-00739-7

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11864-020-00739-7

Keywords

Search

Navigation